Health Condition 1: L649- Androgenic alopecia, unspecified
Conditions
Interventions
Intervention1: Inj. Dutasteride: 2 ml of 0.01% injection dutasteride, deep intradermal, at 60 degree angle 2units at each point in 1 cm grid pattern
will be done Base line, Week 4, Week 8 and Week 12
Sponsors
CUTIS Academy of Cutaneous Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Age abve 18 years – 55 years. Newly diagnosed cases of androgenetic alopecia. Naive cases of AGA and non-responders of topical minoxidil. Baseline serum DHT level within normal range. Females of child-bearing potential agree to use a reliable method of birth control or remain absent during the study Post menopausal females. All other treatments for androgenetic alopecia are prohibited during the course of the study
Exclusion criteria
Exclusion criteria: Patients using the following medications: inhibitors of CYP3A4 (verapamil) or drugs with antiandrogen effect (finasteride) in the last six months. Patients suffering from ejaculatory or erectile dysfunction. Pregnant & breast-feeding females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy and safety of Dutasteride mesotherapy in androgenic alopeciaTimepoint: After 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Trichoscopic assessment will be done at every visit, (Base line, Week 4, week 8, week 12 & week 16) Assessment of hair regrowth will be performed at every visit. Standardized digital photography will be performed at every visit. Timepoint: After 4 months | — |
Countries
India
Contacts
Public ContactDr Megha C
CUTIS Academy of Cutaneous Sciences
Outcome results
None listed